Early access
Sign in
CompletedPhase 3

Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

Key facts

Who runs it
Biohaven Pharmaceuticals, Inc.
Where
Ann Arbor, Austin, Beavercreek, Bellevue, Bellflower, Berlin, Boca Raton, Boise, Boston, Brooklyn, Cedarhurst, Chandler, Chicago, Colton, Coral Gables, Dallas, Decatur, Elgin, Encino, Flowood, Fort Worth, Gaithersburg, Glendale, Great Neck, Hialeah, Houston, Lakeland, Las Vegas, Lauderhill, Los Alamitos, Los Angeles, Media, Methuen, Miami, Miami Springs, Missouri City, Mount Kisco, Naperville, New Haven, New York, North Miami, Norwich, O'Fallon, Oceanside, Orange, Orange City, Orlando, Overland Park, Pembroke Pines, Phoenix, Pikesville, Providence, Redlands, San Jose, Savannah, Sherman Oaks, Springfield, Stanford, Staten Island, Tampa, Toms River, Torrance, Tulsa, Weston, and Winter Park, United StatesSee the 73 sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
456 people enrolled
Started
22 Dec 2020
Ended
27 Oct 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Troriluzole
  • Placebo
Record updated
7 January 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Primary diagnosis of obsessive-compulsive disorder (OCD) as per Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition as confirmed by the MINI at Screening; The duration of the subject's illness must be ≥ 1 year
  • An inadequate response to current Standard of Care medication defined as selective serotonin reuptake inhibitor (excluding fluvoxamine) or clomipramine treatment at an adequate and stable dose for at least 8 weeks prior to screening and at least 12 weeks at baseline (adequate dose defined by USPI labeling); an inadequate response as defined per the MGH-TRQ-OCD, there has been minimal or no meaningful clinical benefit as perceived by the subject
  • Determined by the investigator to be medically stable at baseline/randomization as assessed by medical history, physical examination, laboratory test results, and electrocardiogram testing. Subjects must be physically able and expected to complete the trial as designed

Who cannot take part

  • Subjects with a history of more than two (2) previous failed or inadequate treatment classes given for an adequate duration at an adequate dose as defined by the MGH-TRQ-OCD
  • Current or prior history of: bipolar I or II disorder, schizophrenia or other psychotic disorders, schizoaffective disorder, autism or autistic spectrum disorders, borderline personality disorder, antisocial personality disorder, Tourette's disorder, body dysmorphic disorder, hoarding disorder; or psychosurgery, Deep Brain Stimulation (DBS) or Electroconvulsive Therapy (ECT); or general medical condition that may confound safety and/or efficacy results
  • Previous treatment in a study with troriluzole

Where in United States

  • Michigan Clinical Research Institute PCAnn Arbor, United States
  • BioBehavioral Research of AustinAustin, United States
  • Clinical Inquest Center LtdBeavercreek, United States
  • Northwest Clinical Research CenterBellevue, United States
  • CITrials (Clinical Innovations)Bellflower, United States
  • Hassman Research InstituteBerlin, United States
  • Boca Raton Medical InstituteBoca Raton, United States
  • Northwest Clinical TrialsBoise, United States
  • Boston Clinical TrialsBoston, United States
  • Massachusetts General HospitalBoston, United States
  • Integrative Clinical Trials, LLCBrooklyn, United States
  • Neurobehavioral Research, Inc.Cedarhurst, United States
  • Metropolitan Neuro Behavioral InstituteChandler, United States
  • Uptown Research InstituteChicago, United States
  • Axiom Research, LLCColton, United States
  • Advanced Clinical Research NetworkCoral Gables, United States
  • Relaro Medical TrialsDallas, United States
  • iResearch Atlanta, LLCDecatur, United States
  • Revive Research InstituteElgin, United States
  • WR-PRI, LLC (Encino)Encino, United States
  • Precise Research CentersFlowood, United States
  • North Texas Clinical TrialsFort Worth, United States
  • CBH HealthGaithersburg, United States
  • Behavioral Research Specialists, LLCGlendale, United States
  • Bio Behavioral InstituteGreat Neck, United States
  • Research in Miami IncHialeah, United States
  • Baylor College of MedicineHouston, United States
  • Texas Center for Drug Development, Inc.Houston, United States
  • Lakeland, FloridaHospital not named in the registry
  • Altea ResearchLas Vegas, United States
  • Innovative Clinical Research, Inc.Lauderhill, United States
  • Pharmacology Research InstituteLos Alamitos, United States
  • Clarity Clinical ResearchLos Angeles, United States
  • Suburban Research AssociatesMedia, United States
  • ActivMed Practices and ResearchMethuen, United States
  • Central Miami Medical InstituteMiami, United States
  • FIRCMiami, United States
  • Florida Research Center, Inc.Miami, United States
  • Health Care Family Rehab & ResearchMiami, United States
  • South Florida Research Phase I-IV INCMiami Springs, United States
  • Mt.Olympus Medical Research LLCMissouri City, United States
  • Bioscience Research LLCMount Kisco, United States
  • AMR-Baber Research IncNaperville, United States
  • Yale University/Connecticut Mental Health CenterNew Haven, United States
  • Manhattan Behavioral Medicine PLLCNew York, United States
  • Behavioral Clinical ResearchNorth Miami, United States
  • Comprehensive Psychiatric CareNorwich, United States
  • Psychiatric Care and Research CenterO'Fallon, United States
  • Excell Research, Inc.Oceanside, United States
  • NRC Research InstituteOrange, United States
  • Medical Research Group of Central FloridaOrange City, United States
  • APG Research, LLCOrlando, United States
  • Combined Research Orlando Phase I-IVOrlando, United States
  • Omega Research ConsultantsOrlando, United States
  • Collective Medical ResearchOverland Park, United States
  • MedBio TrialsPembroke Pines, United States
  • IMA Clinical ResearchPhoenix, United States
  • NoeisisPharma, LLCPhoenix, United States
  • Pharmasite Research, IncPikesville, United States
  • Comprehensive Psychiatric Care ProvidersProvidence, United States
  • Anderson Clinical ResearchRedlands, United States
  • Lumos Clinical Research Center LLCSan Jose, United States
  • iResearch SavannahSavannah, United States
  • California Neuroscience Research Medical Group, Inc.Sherman Oaks, United States
  • Sisu at RMGSpringfield, United States
  • Stanford UniversityStanford, United States
  • Richmond Behavioral AssociatesStaten Island, United States
  • Stedman Clinical TrialsTampa, United States
  • Bio Behavioral HealthToms River, United States
  • Collaborative Neuroscience ResearchTorrance, United States
  • Central States Research, LLCTulsa, United States
  • Neurobehaviorial InstituteWeston, United States
  • Conquest Research, LLCWinter Park, United States

About the trial

What the trial wants to find out

The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)

The 2 groups in the trial

  • TroriluzoleExisting treatment, for comparison

    Troriluzole - 2 100mg capsules once daily for the first two weeks. Troriluzole - 2 140mg capsules once daily from week two through week ten.

  • PlaceboPlacebo, for comparison

    Placebo - 2 100mg capsules once daily for the first two weeks. Placebo - 2 140mg capsules once daily from week two through week ten.

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
Record updated
7 January 2026